Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

901 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler.
Bergholtz H, Carter JM, Cesano A, Cheang MCU, Church SE, Divakar P, Fuhrman CA, Goel S, Gong J, Guerriero JL, Hoang ML, Hwang ES, Kuasne H, Lee J, Liang Y, Mittendorf EA, Perez J, Prat A, Pusztai L, Reeves JW, Riazalhosseini Y, Richer JK, Sahin Ö, Sato H, Schlam I, Sørlie T, Stover DG, Swain SM, Swarbrick A, Thompson EA, Tolaney SM, Warren SE, On Behalf Of The GeoMx Breast Cancer Consortium. Bergholtz H, et al. Among authors: prat a. Cancers (Basel). 2021 Sep 4;13(17):4456. doi: 10.3390/cancers13174456. Cancers (Basel). 2021. PMID: 34503266 Free PMC article.
Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials.
Laurberg T, Tramm T, Nielsen T, Alsner J, Nord S, Myhre S, Sørlie T, Leung S, Fan C, Perou C, Gelmon K, Overgaard J, Voduc D, Prat A, Cheang MCU. Laurberg T, et al. Among authors: prat a. Acta Oncol. 2018 Jan;57(1):38-43. doi: 10.1080/0284186X.2017.1401735. Epub 2017 Nov 25. Acta Oncol. 2018. PMID: 29172851 Clinical Trial.
ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer.
Griguolo G, Brasó-Maristany F, González-Farré B, Pascual T, Chic N, Saurí T, Kates R, Gluz O, Martínez D, Paré L, Tsvetkova V, Pesantez D, Vidal M, Adamo B, Muñoz M, Galván P, Barberá L, Cuatrecasas M, Christgen M, Kreipe H, Monge-Escartín I, Villagrasa P, Soy D, Giarratano T, Dieci MV, Conte P, Harbeck N, Guarneri V, Prat A. Griguolo G, et al. Among authors: prat a. Cancers (Basel). 2020 Jul 14;12(7):1902. doi: 10.3390/cancers12071902. Cancers (Basel). 2020. PMID: 32674482 Free PMC article.
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis.
Schettini F, Giuliano M, Giudici F, Conte B, De Placido P, Venturini S, Rognoni C, Di Leo A, Locci M, Jerusalem G, Del Mastro L, Puglisi F, Conte P, De Laurentiis M, Pusztai L, Rimawi MF, Schiff R, Arpino G, De Placido S, Prat A, Generali D. Schettini F, et al. Among authors: prat a. Cancers (Basel). 2021 Mar 22;13(6):1458. doi: 10.3390/cancers13061458. Cancers (Basel). 2021. PMID: 33810205 Free PMC article. Review.
Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts.
Weiss A, Martínez-Sáez O, Waks AG, Laws A, McGrath M, Tarantino P, Portnow L, Winer E, Rey M, Tapia M, Prat A, Partridge AH, Tolaney SM, Cejalvo JM, Mittendorf EA, King TA. Weiss A, et al. Among authors: prat a. Cancer. 2023 Jun 15;129(12):1836-1845. doi: 10.1002/cncr.34750. Epub 2023 Mar 23. Cancer. 2023. PMID: 36951169
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab.
Bueno-Muiño C, Echavarría I, López-Tarruella S, Roche-Molina M, Del Monte-Millán M, Massarrah T, Jerez Y, Ayala de la Peña F, García-Sáenz JÁ, Moreno F, Rodríguez-Lescure Á, Malón-Giménez D, Ballesteros García AI, Marín-Aguilera M, Galván P, Brasó-Maristany F, Waks AG, Tolaney SM, Mittendorf EA, Vivancos A, Villagrasa P, Parker JS, Perou CM, Paré L, Villacampa G, Prat A, Martín M. Bueno-Muiño C, et al. Among authors: prat a. JAMA Oncol. 2023 Jun 1;9(6):841-846. doi: 10.1001/jamaoncol.2023.0187. JAMA Oncol. 2023. PMID: 37103916 Free PMC article.
Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.
Waks AG, Ogayo ER, Paré L, Marín-Aguilera M, Brasó-Maristany F, Galván P, Castillo O, Martínez-Sáez O, Vivancos A, Villagrasa P, Villacampa G, Tarantino P, Desai N, Guerriero J, Metzger O, Tung NM, Krop IE, Parker JS, Perou CM, Prat A, Winer EP, Tolaney SM, Mittendorf EA. Waks AG, et al. Among authors: prat a. JAMA Oncol. 2023 Jun 1;9(6):835-840. doi: 10.1001/jamaoncol.2023.0181. JAMA Oncol. 2023. PMID: 37103927 Free PMC article.
901 results